Sampling and analytic considerations in molecular genetics studies of ADHD. The advantages of predicting phenotype from genotype in ADHD research SIR -The articles on ADHD and the DRD4 in the September 1998 issue of Molecular Psychiatry were very informative. What impressed me most was the expectation that the authors of these articles use as a separate group, 1 or explain why they did not use as a separate group, 2 potential control group recruits which met symptom requirements for ADHD. It has been my experience as a reader of ADHD research that ADHD and control participants tend to be recruited differently (clinical vs non-clinical populations) and that controls tend to be excluded for exhibiting comorbid conditions (ie, conduct disorder) commonly diagnosed in the ADHD participants.
Recruiting the experimental and control groups from different populations may reveal group differences in repeat frequencies unrelated to participant status which may result in both false-positive and false negative results. 3 Secondly, though Castellanos et al's 1 report of a 71% comorbidity rate is quite high, there does tend to be a higher rate of comorbidity in clinicreferred than in non-referred children diagnosed with ADHD. 4 Since it has been put forward that comorbidity may moderate the phenotypic expression of ADHD, 5, 6 it may be necessary to account for the effects of comorbidity on the expression of ADHD when doing genetic research.
I postulate that the best way to avoid the statistical errors associated with the sampling biases listed above is, instead of recruiting on the basis of phenotype and testing for genotype, we should recruit on the basis of genotype and test for phenotype. Considering the present interest in the relationship between the DRD4 and ADHD 7 and the suggestion that the DRD2 is a major moderator of ADHD, 4 I propose that we employ a 5 × 3 factorial design using only those individuals with the 2,2, 2,4, 4,4, 4,7 and 7,7 repeats of the DRD4 gene and the A1,A1, A1,A2 and A2,A2 alleles of the DRD2 gene. The proposed design will not only show the independent effect of each gene on the expression of ADHD and various comorbid conditions (as well as possible interactions), but will also provide a large group of (DRD4) 4,4 repeat, (DRD2) A2,A2 alleles participants that may be used to test the influence of other proposed ADHD genes, such as Cook et al's 3 DAT1. 
V Lavallee

Waldman and Rowe reply
SIR -In her recent letter to Molecular Psychiatry, Ms Lavallee raises a number of interesting issues in genetic research on ADHD. In this comment, we focus on three of these issues regarding the sampling of participants in molecular genetic studies of ADHD. Specifically, we address the issues of choice of controls, the impact of overlapping diagnostic conditions, and the viability of recruiting participants based on genotype vs phenotype. Ms Lavallee raises the appropriate concern that ADHD and comparison groups recruited from different populations might differ in allele frequencies for reasons other than linkage between the disorder and the genetic marker. Although careful matching of cases and controls may overcome this problem to a degree, many potential sources of population stratification exist, some heretofore unknown, that could lead to associations that are not due to the casual effects of the gene. In order to counteract this problem, a number of recent molecular genetic studies of ADHD [1] [2] [3] [4] [5] have used a within-family statistical procedure, the Transmission Disequilibrium Test (TDT), 6 that protects against the biasing effects of population stratification. The TDT contrasts the transmission of high-risk vs low-risk alleles from heterozygous parents to their affected children. Use of the TDT should eliminate any population stratification biases incurred in the comparison of ADHD cases with controls, which may be drawn from populations with characteristics that differ in important ways.
